These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9013191)

  • 1. N-(Hydroxymethyl) melamines.
    Coley HM
    Gen Pharmacol; 1997 Feb; 28(2):177-82. PubMed ID: 9013191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.
    Coley HM; Jarman M; Brooks N; Kubota T; Goddard PM; Jones M; Lee N; Owens MD; Halbert GW; Judson IR
    Int J Cancer; 1996 Nov; 68(3):356-63. PubMed ID: 8903478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.
    Coley HM; Jarman M; Jones M; Sargent JM; Kubota T; Lee NC; Goddard PM; Elgie AW; Williamson C; Taylor CG; Judson IR
    Anticancer Res; 1996; 16(4A):1851-5. PubMed ID: 8712712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
    Rutty CJ; Judson IR; Abel G; Goddard PM; Newell DR; Harrap KR
    Cancer Chemother Pharmacol; 1986; 17(3):251-8. PubMed ID: 3091280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
    Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
    Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines.
    Coley HM; Jarman M; Brooks N; Thornton TJ; Judson IR
    Eur J Cancer; 1994; 30A(12):1827-36. PubMed ID: 7880614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies.
    Coley HM; Brooks N; Phillips DH; Hewer A; Jenkins TC; Jarman M; Judson IR
    Biochem Pharmacol; 1995 May; 49(9):1203-12. PubMed ID: 7763301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
    Judson IR; Rutty CJ; Abel G; Graham MA
    Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
    Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
    Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
    Markman M; Blessing JA; Moore D; Ball H; Lentz SS
    Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
    Broggini M; Rossi C; Colombo T; D'Incalci M
    Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexamethylmelamine and pentamethylmelamine: an update.
    Hahn DA
    Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
    Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
    Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of pentamethylmelamine.
    Ajani JA; Cabanillas FF; Bodey GP
    Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexamethylmelamine: a critical review of an active drug.
    Foster BJ; Harding BJ; Leyland-Jones B; Hoth D
    Cancer Treat Rev; 1986 Dec; 13(4):197-217. PubMed ID: 3102057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
    Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
    Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
    [No Abstract]   [Full Text] [Related]  

  • 19. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
    Cumber AJ; Ross WC
    Chem Biol Interact; 1977 Jun; 17(3):349-57. PubMed ID: 407012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of hexamethylmelamine on human tumor xenografts serially transplanted in nude mice.
    Kubota T; Tanino H; Watanabe M; Kitajima M
    Anticancer Res; 1994; 14(6B):2521-4. PubMed ID: 7872676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.